724 related articles for article (PubMed ID: 19883329)
1. Plasmodium falciparum: new molecular targets with potential for antimalarial drug development.
Gardiner DL; Skinner-Adams TS; Brown CL; Andrews KT; Stack CM; McCarthy JS; Dalton JP; Trenholme KR
Expert Rev Anti Infect Ther; 2009 Nov; 7(9):1087-98. PubMed ID: 19883329
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of purine N9-[2-hydroxy-3-O-(phosphonomethoxy)propyl] derivatives and their side-chain modified analogs as potential antimalarial agents.
Krečmerová M; Dračínský M; Hocková D; Holý A; Keough DT; Guddat LW
Bioorg Med Chem; 2012 Feb; 20(3):1222-30. PubMed ID: 22249123
[TBL] [Abstract][Full Text] [Related]
3. Hemoglobin Degrading Proteases of Plasmodium falciparum as Antimalarial Drug Targets.
Qidwai T
Curr Drug Targets; 2015; 16(10):1133-41. PubMed ID: 25738296
[TBL] [Abstract][Full Text] [Related]
4. Helicases - feasible antimalarial drug target for Plasmodium falciparum.
Tuteja R
FEBS J; 2007 Sep; 274(18):4699-704. PubMed ID: 17824956
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of branched 9-[2-(2-phosphonoethoxy)ethyl]purines as a new class of acyclic nucleoside phosphonates which inhibit Plasmodium falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase.
Hocková D; Holý A; Masojídková M; Keough DT; de Jersey J; Guddat LW
Bioorg Med Chem; 2009 Sep; 17(17):6218-32. PubMed ID: 19666228
[TBL] [Abstract][Full Text] [Related]
6. Plasmepsins as potential targets for new antimalarial therapy.
Ersmark K; Samuelsson B; Hallberg A
Med Res Rev; 2006 Sep; 26(5):626-66. PubMed ID: 16838300
[TBL] [Abstract][Full Text] [Related]
7. Downstream effects of haemoglobinase inhibition in Plasmodium falciparum-infected erythrocytes.
Naughton JA; Nasizadeh S; Bell A
Mol Biochem Parasitol; 2010 Oct; 173(2):81-7. PubMed ID: 20478341
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of Plasmepsin II-potential antimalarial agents.
Corminboeuf O; Dunet G; Hafsi M; Grimont J; Grisostomi C; Meyer S; Binkert C; Bur D; Jones A; Prade L; Brun R; Boss C
Bioorg Med Chem Lett; 2006 Dec; 16(24):6194-9. PubMed ID: 17000102
[TBL] [Abstract][Full Text] [Related]
9. Design of new plasmepsin inhibitors: a virtual high throughput screening approach on the EGEE grid.
Kasam V; Zimmermann M; Maass A; Schwichtenberg H; Wolf A; Jacq N; Breton V; Hofmann-Apitius M
J Chem Inf Model; 2007; 47(5):1818-28. PubMed ID: 17727268
[TBL] [Abstract][Full Text] [Related]
10. [Transport proteins as drug targets in Plasmodium falciparum. New perspectives in the treatment of malaria].
Ellekvist P; Colding H
Ugeskr Laeger; 2006 Mar; 168(13):1314-7. PubMed ID: 16579884
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, biological evaluation, and modeling studies of inhibitors aimed at the malarial proteases plasmepsins I and II.
Muthas D; Nöteberg D; Sabnis YA; Hamelink E; Vrang L; Samuelsson B; Karlén A; Hallberg A
Bioorg Med Chem; 2005 Sep; 13(18):5371-90. PubMed ID: 16054370
[TBL] [Abstract][Full Text] [Related]
12. Antimalarial drugs and drug targets specific to fatty acid metabolic pathway of Plasmodium falciparum.
Qidwai T; Khan F
Chem Biol Drug Des; 2012 Aug; 80(2):155-72. PubMed ID: 22487082
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of hypoxanthine-guanine phosphoribosyltransferase by acyclic nucleoside phosphonates: a new class of antimalarial therapeutics.
Keough DT; Hocková D; Holý A; Naesens LM; Skinner-Adams TS; Jersey Jd; Guddat LW
J Med Chem; 2009 Jul; 52(14):4391-9. PubMed ID: 19527031
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of novel N-branched acyclic nucleoside phosphonates as potent and selective inhibitors of human, Plasmodium falciparum and Plasmodium vivax 6-oxopurine phosphoribosyltransferases.
Hocková D; Keough DT; Janeba Z; Wang TH; de Jersey J; Guddat LW
J Med Chem; 2012 Jul; 55(13):6209-23. PubMed ID: 22725979
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of Plasmodium falciparum methionine aminopeptidase 1b possess antimalarial activity.
Chen X; Chong CR; Shi L; Yoshimoto T; Sullivan DJ; Liu JO
Proc Natl Acad Sci U S A; 2006 Sep; 103(39):14548-53. PubMed ID: 16983082
[TBL] [Abstract][Full Text] [Related]
16. Plasmodium falciparum neutral aminopeptidases: new targets for anti-malarials.
Skinner-Adams TS; Stack CM; Trenholme KR; Brown CL; Grembecka J; Lowther J; Mucha A; Drag M; Kafarski P; McGowan S; Whisstock JC; Gardiner DL; Dalton JP
Trends Biochem Sci; 2010 Jan; 35(1):53-61. PubMed ID: 19796954
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, antimalarial evaluation and molecular modeling studies of hydroxyethylpiperazines, potential aspartyl protease inhibitors, part 2.
Cunico W; Gomes CR; Facchinetti V; Moreth M; Penido C; Henriques MG; Varotti FP; Krettli LG; Krettli AU; da Silva FS; Caffarena ER; de Magalhães CS
Eur J Med Chem; 2009 Sep; 44(9):3816-20. PubMed ID: 19403210
[TBL] [Abstract][Full Text] [Related]
18. Plasmepsins IX and X are essential and druggable mediators of malaria parasite egress and invasion.
Nasamu AS; Glushakova S; Russo I; Vaupel B; Oksman A; Kim AS; Fremont DH; Tolia N; Beck JR; Meyers MJ; Niles JC; Zimmerberg J; Goldberg DE
Science; 2017 Oct; 358(6362):518-522. PubMed ID: 29074774
[TBL] [Abstract][Full Text] [Related]
19. Strategies to reverse drug resistance in malaria.
Egan TJ; Kaschula CH
Curr Opin Infect Dis; 2007 Dec; 20(6):598-604. PubMed ID: 17975410
[TBL] [Abstract][Full Text] [Related]
20. Mechanism-based inhibitors of the aspartyl protease plasmepsin II as potential antimalarial agents.
Gupta D; Yedidi RS; Varghese S; Kovari LC; Woster PM
J Med Chem; 2010 May; 53(10):4234-47. PubMed ID: 20438064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
